GPCR GPCR
Company Profile ↓Company Overview
GPCR (GPCR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +201.13% |
| 6 Months: | -39.69% |
| 3 Months: | +22.94% |
| 1 Month: | -10.77% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.97 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 46.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -12.95M | -13.96M | -12.69M | -19.65M | -25.99M | -26.14M | -32.02M | -33.32M | -45.84M | -56.31M | -70.45M | -73.79M | -89.38M |
| Net Income | -13.08M | -13.95M | -12.42M | -17.98M | -23.28M | -23.86M | -26.04M | -26.03M | -33.98M | -46.83M | -61.66M | -65.71M | -75.97M |
| Diluted EPS | -1.44 | -1.64 | -1.27 | -0.25 | -0.20 | -0.21 | -0.19 | -0.18 | -0.20 | -0.27 | - | -0.37 | -0.35 |
| R&D Expense | 8.49M | 10.18M | 9.16M | 13.13M | 19.41M | 17.52M | 20.68M | 22.05M | 32.60M | 42.87M | 54.71M | 58.99M | 66.51M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -52.56M | -102.78M | -158.23M | -176.56M |
| Net Income | -51.32M | -89.62M | -122.53M | -141.20M |
| Diluted EPS | -5.51 | -0.81 | -0.78 | -0.80 |
| R&D Expense | 36.19M | 70.10M | 108.81M | 225.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 97.84M | 482.02M | 903.33M | 1.58B |
| Total Equity | -64.73M | -115.14M | 452.97M | 864.84M | 1.52B |
| Cash & Equivalents | - | 26.09M | 129.79M | 169.51M | 799.62M |
| Total Liabilities | - | 13.01M | 29.05M | 38.49M | 67.54M |
| Current Liabilities | - | 13.01M | 24.74M | 36.02M | 63.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -46.12M | -79.49M | -116.64M | -222.20M |
| Investing Cash Flow | -62.11M | -268.34M | -358.91M | 89.80M |
| Financing Cash Flow | 29.01M | 451.53M | 515.26M | 762.52M |
| Capital Expenditure | -155.00K | -2.17M | -1.29M | -3.61M |
| Free Cash Flow | -46.27M | -81.66M | -117.93M | -225.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 44.6% | -19.8% | -14.2% | -9.3% |
| ROCE % | -62.0% | -22.5% | -18.2% | -11.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GPCR
Price to earnings forward of Structure Therapeutics Inc. – NASDAQ:GPCR - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNQmRqWVltV25NTjBiSHVXMzRNVlZlRWIwZ09JSlFRZ2hIcEhBMVNRQ2Y1ZUlQTW5INmlLa3Nab21qWWZtMTdrTFdlSU1Ld0pqYk5hNERzbnc0bXBGTUl4Z25VYi1Dc3Q3M1M2ZlZISnpCSjZpeEVIZExvYnB1RHdVcUVxdVduZ0llLVhDTF…
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPdXdnWnJySVF3SW9VcUpYd255ZC1VSF96cGhpS1FpVkk2b2JhSzdpYkpJUTRvZjFIbS0tNVc0TkUxMG5MS1JaVzVsRTdERTRCRjdSTHg1VExOZG1HMG1rYWRoanhLTWF4dFllTjJiY2lWZTdiM1hSaHpGeDRZd0JJQjl6cHJlSUFpMU15cF…
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNWHpkZWYwYXN0cVkweTNqN0JMMjFhNlRhQzJXeGpEYnZBVmxHY2g1bFBNQVZ0UmU4WjZCTGtTUFlhQ0pySkpsbGhSbVFvX3Z0ZXRDSldJMklWZXhOZDFDY1BrZDFDOTJDSkhDNV9MbFhPRHcxNzRqdWx3VUhCZmg3WkFZaVI4MFRzYWFvRE…
Structure Therapeutics (GPCR) Stock After Phase 2b Obesity Data What Does A 2x P/B Multiple Suggest? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOWnZNQVFCeGJpRGhUM1J6SkF2YjNpSjkwek9oRVZvejZia1hVWEd2alB4bVM1OGdLb1ZNS2lRbDYyWFNEc19ReEplTnFLZ2lvdjFveWEzc3Nyc0dXcXlzWmVpRXVRcEpWVldyYUJtc21iOENDUmR0amlDVy1mdDIwUkNRVEV5LXBqRlBQLX…
Structure Therapeutics Inc. (GPCR) Stock Analysis: A Promising Biotech with a 115% Upside Potential - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNejB5UDZ4ODNhR0pYTWF4S2ZEYVJUaW5zSU9IWlo3OFl0b1BwZlRvMXh5VGZCR3FyNHp1OEdrQUp5QmhFZlFTR3pETkpEa1RfZXBjMEY0b1ZtVnNqbXBWSDNaQk9tMzlnMlJjR21ReV9peE8tN1FKSFpGSnVNX3ZwWUpNSWpDRVdDV3dVNW…
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - The Manila Times
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNdVlZQ1Rrc1pMN0FxTVBaSXg3ZnBDcGlpdTdYXzNaVTktVVVSU2VmZmRUWjVQSUtibXoxWWlVWVVQNXdZYjZDVTRtY0RjTkFQVlRJUzJCcy1Xd0JtNXhYUkh0U3VsVjc5Z2ZDYkg5RUtFM3F5SFo2WHVXSEtmbkdMVEpfNEluWkJOck90Z0…
GPCR — Frequently Asked Questions
What is the current share price of GPCR?
As of 2026-08-05 17:25 PDT, GPCR trades at $50.53 on NASDAQ/NYSE. Its 52-week range is $16.20 to $93.79.
What is the P/E ratio of GPCR?
GPCR trades at a trailing price-to-earnings (P/E) ratio of -63.16.
What is the return on equity (ROE) of GPCR?
GPCR has a return on equity (ROE) of -9.31%. Its return on capital employed (ROCE) is -11.61%.
Is GPCR a good stock to buy?
This page provides a data-driven analysis of GPCR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.